, Tracking Stock Market Picks
Enter Symbol:

Mkt Outperform
down 45.27 %

ONCOTHYREON (ONTY) rated Mkt Outperform with price target $14 by JMP Securities

Posted on: Tuesday,  Jan 24, 2012  9:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform ONCOTHYREON (NASDAQ: ONTY) on 01/24/2012, when the stock price was $6.45. Since
then, ONCOTHYREON has lost 45.27% as of 01/14/2016's recent price of $3.53.
If you would have followed this JMP Securities's recommendation on ONTY, you would have lost 45.27% of your investment in 1451 days.

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company?s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon?s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company?s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2012 9:25 AM Buy
6.45 14.00
as of 12/31/2012
1 Week up  1.58 %
1 Month down  -58.07 %
3 Months down  -62.57 %
1 YTD down  -70.23 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy